Prof Claire Harrison at ASH 2014: Highlights on myeloproliferative neoplasms

Prof Claire Harrison (Guy’s and St Thomas’ NHS Foundation Trust, London, UK) presents highlights on myeloproliferative neoplasms (MPN) at the 2014 American Society of Hematology (ASH) Annual Meeting.

A molecular-based approach in MPN studies, which has improved understanding of driver mutations, has rapidly increased recent advances in clinical management. Combinational therapies are in preliminary stages and focus is on the Janus kinase (JAK) inhibitor, ruxolitinib, in combinations that enhance overall patient response. Long-term studies, such as the Evaluation of Xagrid Efficacy and Long-term Safety (EXELS) study are providing insight in high-risk patients with essential thrombocythemia (ET). Quality of life in MPN patients is also addressed.

Year of Production:
Running Time:


Comments are closed.